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Time to Reassess the Speciﬁc Impact of Drug Therapy in
Coronary Heart Disease PatientsWe thank Dr. Delgado-Almeida for his interest in our
paper (1).
We agree that control of angina and improvement
of quality of life are important goals of treatment, but
we do not have data on the effect of beta-blocker
treatment on these patient-related outcomes. It is
important to note that treatments may relieve angina
symptoms with no effect on mortality (and vice versa)
and that relief of angina remains an important indi-
cation for treatment.
Dr. Delgado-Aleida’s comments about the role of
the capillary bed, oxygen binding, red blood celldeformation, and vasodilation are interesting and
deserve to be investigated. Irrespective of possible
mechanisms of action, we need reliable empirical
evidence about actual clinical outcomes to inform
treatment decisions.*Mark A. Hlatky, MD
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